SEK 14.50
-0.38 (-2.55%)
SEK · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ORX.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 4 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use DisorderNCT04948307results2025-06-27Treatment Success RateRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: OXD01 digital therapy · Other: Standard of Care | Opioid-use Disorder | 437 | 2023-04-12actual | 2025-06-27 |
| Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid DependenceNCT01903005results2015-10-28Number of Patients Reporting Treatment-Emergent Adverse EventsOpen-label · Treatment | Phase 4 | Completed | Drug: Higher bioavailability BNX sublingual tablets | Opioid Dependence, on Agonist Therapy | 668 | Sep 2014actual | 2015-10-28 |
| Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent AdultsNCT01908842results2015-05-22Primary Endpoints of Retention in Treatment at Days 3 and 15Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: BNX sublingual tablets, BNX sublingual film, Buprenorphine | Opioid Dependence, on Agonist Therapy | 759 | Apr 2014actual | 2017-05-10 |
| Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid DependenceNCT01848054results2015-06-24Retention in Treatment in the Per Protocol PopulationRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Buprenorphine/naloxone sublingual tablets, Buprenorphine | Opioid-Related Disorders, Opiate Dependence | 313 | Jan 2014actual | 2017-05-10 |
| Conversion From Fast Acting Oral Opioids to Abstral®NCT01315886Response rate in patients converted to SL fentanyl.Open-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Recruitment difficulties | Drug: SL fentanyl | Pain | 8 | 2011-12-07actual | 2017-04-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19